A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Evobrutinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono
- 21 Jun 2017 Planned End Date changed from 1 Dec 2019 to 10 Jan 2020.
- 30 Jan 2017 Status changed from not yet recruiting to recruiting.
- 02 Dec 2016 New trial record